Detalhe da pesquisa
1.
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
J Urol
; 211(2): 241-255, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37922370
2.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-up From a Phase 3 Trial.
J Urol
; : 101097JU0000000000004020, 2024 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704840
3.
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Lancet Oncol
; 22(1): 107-117, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33253641
4.
Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.
J Urol
; 205(6): 1612-1621, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33502236
5.
Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
BJU Int
; 128(5): 568-574, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33484074
6.
The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
BJU Int
; 128(1): 65-71, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33210440
7.
Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis.
J Sex Med
; 17(10): 1995-2004, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32713807
8.
Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.
BJU Int
; 119(5): 684-691, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27753185
9.
Reply by Authors.
J Urol
; 205(6): 1620-1621, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33734859
10.
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.
Ann Surg Oncol
; 23(12): 4110-4114, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27387678
11.
Genetic Variants in the Wnt/ß-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk.
J Urol
; 194(6): 1771-6, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26173102
12.
Genetic subtypes of invasive bladder cancer.
Curr Opin Urol
; 25(5): 449-58, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26218634
13.
Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
Cancer
; 120(12): 1794-9, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24633966
14.
Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
J Urol
; 191(1): 40-7, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23911605
15.
Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review.
BJU Int
; 113(5b): E28-33, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24053608
16.
Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
J Urol
; 190(3): 850-6, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23507396
17.
Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma.
BJU Int
; 111(7): 1068-74, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23551693
18.
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval.
Front Immunol
; 14: 1260498, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37705979
19.
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Eur Urol Oncol
; 6(6): 611-620, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37833193
20.
Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy.
BJU Int
; 110(11 Pt B): E590-5, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22758775